Kevzara (sarilumab) vs Jyseleca (filgotinib)

Kevzara (sarilumab) and Jyseleca (filgotinib) are both used to treat rheumatoid arthritis, but they work in different ways: Kevzara is an interleukin-6 (IL-6) receptor antagonist, which blocks the activity of IL-6, a protein involved in inflammatory responses, whereas Jyseleca is a Janus kinase (JAK) inhibitor, targeting enzymes involved in the inflammation pathway. Kevzara is administered as a subcutaneous injection, while Jyseleca is taken orally as a tablet, which may influence patient preference based on convenience and comfort with administration methods. The choice between Kevzara and Jyseleca should be made in consultation with a healthcare provider, considering individual patient factors such as disease severity, comorbid conditions, previous treatment responses, and potential side effects.

Difference between Kevzara and Jyseleca

Metric	Kevzara (sarilumab)	Jyseleca (filgotinib)
Generic name	Sarilumab	Filgotinib
Indications	Moderate to severe rheumatoid arthritis	Rheumatoid arthritis, Ulcerative colitis
Mechanism of action	Interleukin-6 receptor antagonist	Janus kinase (JAK) inhibitor
Brand names	Kevzara	Jyseleca
Administrative route	Subcutaneous injection	Oral
Side effects	Upper respiratory infections, elevated liver enzymes, injection site reactions	Nausea, upper respiratory infections, liver enzyme elevation
Contraindications	Hypersensitivity to sarilumab or excipients, active infection	Hypersensitivity to filgotinib or excipients, severe liver disease
Drug class	Monoclonal antibody	Janus kinase inhibitor
Manufacturer	Sanofi and Regeneron Pharmaceuticals	Gilead Sciences

Efficacy

Kevzara (Sarilumab) for Rheumatoid Arthritis

Kevzara (sarilumab) is a monoclonal antibody specifically designed to block the interleukin-6 (IL-6) receptor, which plays a key role in the inflammatory process of rheumatoid arthritis (RA). Clinical trials have demonstrated the efficacy of Kevzara in reducing the signs and symptoms of RA in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). In these studies, Kevzara has shown to improve physical function and slow the progression of joint damage in patients with moderate to severe RA.

The efficacy of Kevzara was evaluated in several pivotal trials, including the MOBILITY and the TARGET studies. In the MOBILITY trial, patients treated with Kevzara in combination with methotrexate achieved significantly greater improvements in the American College of Rheumatology (ACR) criteria for 20% improvement (ACR20) compared to placebo. The TARGET study, which involved patients who did not respond adequately to or were intolerant to TNF inhibitors, also reported improvements in ACR20 response rates with Kevzara compared to placebo.

Jyseleca (Filgotinib) for Rheumatoid Arthritis

Jyseleca (filgotinib) is a selective Janus kinase (JAK) inhibitor used in the treatment of adults with moderate to severe rheumatoid arthritis. It works by interfering with the JAK-STAT signaling pathway, which is known to contribute to the inflammatory and immune processes in RA. Jyseleca has been shown to reduce symptoms, improve physical function, and inhibit the progression of structural damage in RA patients who have had an inadequate response to one or more DMARDs, including methotrexate.

The efficacy of Jyseleca has been established through various clinical trials, including the FINCH 1, FINCH 2, and FINCH 3 studies. These trials demonstrated that patients receiving Jyseleca achieved higher ACR20 response rates compared to placebo and, in some cases, compared to a standard biologic treatment. Notably, in the FINCH 1 trial, filgotinib in combination with methotrexate was more effective in achieving ACR20 responses than methotrexate alone. Additionally, Jyseleca has been associated with improvements in Health Assessment Questionnaire Disability Index (HAQ-DI) scores, which measure the impact of RA on daily living activities.

Regulatory Agency Approvals

Kevzara

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Jyseleca

European Medical Agency (EMA), European Union
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Kevzara or Jyseleca today

If Kevzara or Jyseleca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Kevzara

Buy Jyseleca

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: